Allspring Global Investments Holdings LLC Acquires 5,668 Shares of Haemonetics Co. (NYSE:HAE)

Allspring Global Investments Holdings LLC grew its holdings in Haemonetics Co. (NYSE:HAE) by 0.7% in the 4th quarter, Holdings Channel reports. The fund owned 801,049 shares of the medical instruments supplier’s stock after purchasing an additional 5,668 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Haemonetics were worth $62,802,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its position in shares of Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after acquiring an additional 632 shares during the period. KBC Group NV lifted its position in Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 712 shares during the period. iSAM Funds UK Ltd bought a new position in Haemonetics in the third quarter worth $204,000. CWC Advisors LLC. bought a new position in Haemonetics in the third quarter worth $231,000. Finally, Versor Investments LP lifted its position in Haemonetics by 9.1% in the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock worth $289,000 after purchasing an additional 300 shares during the period. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Up 1.6 %

Shares of NYSE:HAE opened at $62.27 on Friday. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.09 and a current ratio of 3.97. The company’s fifty day moving average is $74.92 and its 200-day moving average is $77.69. The company has a market capitalization of $3.13 billion, a PE ratio of 24.51, a P/E/G ratio of 0.98 and a beta of 0.39.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Equities research analysts predict that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HAE has been the subject of several research reports. Needham & Company LLC reduced their target price on Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Barrington Research reduced their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price for the company. Finally, JMP Securities reduced their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.